Company Overview - Oculis Holding AG is a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs [20] - The company is developing a differentiated pipeline of innovative product candidates, including OCS-01 for diabetic macular edema (DME) and Licaminlimab for dry eye disease (DED) [20] Upcoming Presentations - Oculis will present its late-stage pipeline at several key conferences, including Eyecelerator 2025, ARVO Annual Meeting, and Retina World Congress [1][2][3] - The presentations will cover interim results from the DME AWARE Delphi Study and insights from the Phase 3 DIAMOND program regarding OCS-01 eye drops for DME [2][3] Product Details - OCS-01 is an investigational eye drop formulation designed to treat DME non-invasively, aiming to transform the treatment paradigm by providing an alternative to invasive methods like intravitreal injections [13][14] - Licaminlimab (OCS-02) is being developed as a topical biologic anti-TNFα eye drop for DED, with a focus on personalized treatment approaches based on genetic biomarkers [16][19] Market Context - DME currently affects approximately 37 million people globally, with projections to rise to 53 million by 2040 due to increasing diabetes prevalence [15] - DED impacts over 110 million people in G7 countries, with a significant portion of patients remaining unsatisfied with current treatment options [18][19]

Core Insights - Oculis Holding AG is presenting its innovative late-stage pipeline at major ophthalmology conferences, including Eyecelerator 2025, ARVO Annual Meeting, and Retina World Congress [1][2][3] Pipeline Developments - The DME AWARE Delphi Study interim results will focus on unmet needs in diabetic macular edema (DME) patient management, with insights from the Phase 3 DIAMOND program on OCS-01 eye drops [2][7] - OCS-01 is being developed as the first non-invasive treatment for DME, addressing the need for earlier intervention and for patients who do not respond adequately to current treatments [2][13] - Licaminlimab (OCS-02) is being investigated for dry eye disease (DED) and has shown positive results in Phase 2 trials, with a genetic biomarker identified to predict patient response [3][16] Conference Presentations - Oculis will showcase its developments at the following events: - Eyecelerator 2025 on May 2, 2025, featuring TKI and Drug Delivery [4] - ARVO Annual Meeting on May 5, 2025, presenting interim results of the DME AWARE Delphi Study [7] - Retina World Congress on May 8, 2025, discussing Licaminlimab in DED treatment [7] Market Context - DME currently affects approximately 37 million people globally, with projections to rise to 53 million by 2040 due to increasing diabetes prevalence [15] - DED impacts over 110 million people in G7 countries, with a significant portion of patients remaining unsatisfied with current treatment options [18][19] Company Overview - Oculis is a biopharmaceutical company focused on addressing significant unmet medical needs in ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for DME and Licaminlimab for DED [20]

ZUG, Switzerland, April 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01. The issuance comprises 589,974 registered shares, reflecting the settlement of 310,941 shares issued in connection with the exercise of equity awards under the Company’s Stock Option and Incentive Plan Regulation and 279,033 shares issued through EBAC warran ...

Core Points - Oculis Holding AG announces the continuation of the Ramin Tadayoni Award in collaboration with EURETINA to honor the legacy of Professor Tadayoni, focusing on innovative research in retinal diseases [1][2] - The award provides €30,000 for research support and an additional €5,000 for the candidate, aimed at postgraduate scholars in retina research, with applications open until May 12, 2025 [3] - The inaugural recipient of the award in 2024 was Dr. Andrea Govetto, who is developing a computational model for macular edema [4] Company Overview - Oculis is a global biopharmaceutical company focused on ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for diabetic macular edema, Privosegtor for acute optic neuritis, and Licaminlimab for dry eye disease [6] - The company is headquartered in Switzerland and operates in the U.S. and Iceland, led by an experienced management team supported by international healthcare investors [6]

Core Viewpoint - Oculis Holding AG is hosting an R&D Day to provide updates on its late-stage clinical candidates and future development strategies, emphasizing its commitment to addressing unmet medical needs in ophthalmic and neuro-ophthalmic diseases [1][2]. Group 1: Event Details - The R&D Day will take place on April 15, 2025, from 10:00 AM to 12:00 PM ET at the Intercontinental New York Barclay hotel, with options for in-person and virtual attendance [1]. - The event will include presentations from key opinion leaders and a live Q&A session following the formal presentations [2][3]. Group 2: Clinical Pipeline Updates - Oculis will provide updates on three innovative late-stage clinical candidates: OCS-01 for diabetic macular edema (DME), Licaminlimab (OCS-02) for dry eye disease (DED), and Privosegtor (OCS-05) for acute optic neuritis [5][6]. - Enrollment for the Phase 3 DIAMOND trials of OCS-01 has been completed with over 800 patients, and topline data is expected in Q2 2026 [6]. - The development plan for Licaminlimab (OCS-02) aims to adopt a genotype-based personalized approach in DED, with a Phase 2/3 study anticipated to start in the second half of 2025 [6]. Group 3: Future Development Plans - Oculis will announce two new programs utilizing Privosegtor (OCS-05) for treating non-arteritic anterior ischemic optic neuritis (NAION) and for managing acute relapses in multiple sclerosis (MS) patients [6]. - The company is focused on maximizing resources and driving value through its portfolio prioritization strategy [2]. Group 4: Upcoming Investor Meeting - An investor meeting will be held in Iceland on April 29, 2025, where Oculis management and ophthalmology experts will discuss the late-stage pipeline [4].

ZUG, Switzerland, April 15, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, will host an in-person and virtual R&D Day today, Tuesday, April 15, 2025 from 10:00 AM to 12:00 PM ET at the Intercontinental New York Barclay hotel. To attend the event or participate virtually, please register here. The event will prov ...

DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME)Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an industry-leading record speed across 119 sites worldwide primarily in the US; topline data readout expected in Q2 2026 with NDA submission to followCompany to provide an update on the DIAMOND program and its innovative late-stage pipeline at the upcoming in-person and virtual R&D Day on Tuesday, April 15 ZUG, S ...

ZUG, Switzerland, April 10, 2025 (GLOBE NEWSWIRE) -- DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME)Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an industry-leading record speed across 119 sites worldwide primarily in the US; topline data readout expected in Q2 2026 with NDA submission to followCompany to provide an update on the DIAMOND program and its innovative late-stage pipeline at the upcoming in-p ...

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it will host an in-person and virtual R&D Day on Tuesday, April 15, 2025 from 10:00 AM to 12:00PM ET at the Intercontinental New York Barclay hotel. To register for the event, click here. About OCS-01 eye drops and the OPTIREACH® ...

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it will host an in-person and virtual R&D Day on Tuesday, April 15, 2025 from 10:00 AM to 12:00PM ET at the Intercontinental New York Barclay hotel. To register for the event, click here. The event will provide an upd ...